Now showing items 1-1 of 1

    • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. 

      von Minckwitz, G; Procter, M; de Azambuja, E; Zardavas, D; Benyunes, M; Viale, G; Suter, T; Arahmani, A; Rouchet, N; Clark, E; Knott, A; Lang, I; Levy, C; Yardley, DA; Bines, J; Gelber, RD; Piccart, M; Baselga, J; APHINITY Steering Committee and Investigators (2017-07)
      BACKGROUND:Pertuzumab increases the rate of pathological complete response in the preoperative context and increases overall survival among patients with metastatic disease when it is added to trastuzumab and chemotherapy ...